Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
INO
$1.89
$
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Next Earnings
2026-02-25
Beta
1.743
Average Volume
Market Cap
Last Dividend
CIK
0001055726
ISIN
US45773H4092
CUSIP
45773H201
CEO
Jacqueline E. Shea
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
134
IPO Date
1998-12-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| INOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm | Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options | GlobeNewsWire | 2026-02-24 17:57:00 |
| ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO | New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | Newsfile Corp | 2026-02-24 16:13:00 |
| Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO | NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 26-cv-00803, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Inovio securities between October 10, 2023 and December 26, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. | GlobeNewsWire | 2026-02-24 16:04:00 |
| INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm | LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 7, 2026. | GlobeNewsWire | 2026-02-24 10:16:00 |
| Investors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO | NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. | PRNewsWire | 2026-02-24 09:00:00 |
| Holzer & Holzer, LLC Reminds INO Investors of the April 7, 2026 Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Securities Class Action | ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Inovio's business, operations, and prospects, including allegations that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated. | GlobeNewsWire | 2026-02-24 08:00:00 |
| INO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 | Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. | Newsfile Corp | 2026-02-23 19:22:00 |
| ROSEN, A LONGSTANDING FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO | New York, New York--(Newsfile Corp. - February 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | Newsfile Corp | 2026-02-23 16:08:00 |
| Levi & Korsinsky, LLP: Cellectra Device Manufacturing Practices at Center of Inovio Pharmaceuticals Securities Litigation | Important Notice Regarding Alleged Medical Device Manufacturing Misrepresentations Important Notice Regarding Alleged Medical Device Manufacturing Misrepresentations | GlobeNewsWire | 2026-02-23 15:51:00 |
| Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | LOS ANGELES, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). | GlobeNewsWire | 2026-02-23 13:06:00 |
| Is Inovio Pharmaceuticals Stock Going to $0? | Inovio Pharmaceuticals' innovative DNA platform could soon lead to an approval. However, the company still faces serious obstacles in the near and medium term. | The Motley Fool | 2026-02-23 06:34:00 |
| Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO | LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or "the Company") (NASDAQ: INO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. | PRNewsWire | 2026-02-23 04:04:00 |
| INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm | LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or "the Company") (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 7, 2026. | PRNewsWire | 2026-02-23 04:02:00 |
| ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO | New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | Newsfile Corp | 2026-02-22 14:28:00 |
| ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO | NEW YORK, Feb. 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. | Globe News Wire | 2026-02-22 09:33:00 |
| INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit | NEW YORK, Feb. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. So what: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | PRNewsWire | 2026-02-21 18:05:00 |
| ROSEN, A LEADING NATIONAL FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO | New York, New York--(Newsfile Corp. - February 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | Newsfile Corp | 2026-02-21 13:46:00 |
| INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm | LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 7, 2026. | GlobeNewsWire | 2026-02-20 14:37:00 |
| Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR INOVIO INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURS. | Business Wire | 2026-02-20 13:41:00 |
| ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO | New York, New York--(Newsfile Corp. - February 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | Newsfile Corp | 2026-02-20 13:12:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-01-30 | 2026-01-30 | View Filing |
| 424B5 | 2026-01-27 | 2026-01-27 | View Filing |
| 8-K | 2026-01-27 | 2026-01-27 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| SC 13G/A | 2025-12-08 | 2025-12-08 | View Filing |
| SC 13G | 2025-12-05 | 2025-12-05 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13G/A | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-07 | 2025-07-07 | View Filing |
| 424B5 | 2025-07-03 | 2025-07-03 | View Filing |
| 424B5 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G | 2025-04-30 | 2025-04-30 | View Filing |
| SC 13G/A | 2025-04-17 | 2025-04-17 | View Filing |
| ARS | 2025-04-07 | 2025-04-07 | View Filing |
| DEF 14A | 2025-04-07 | 2025-04-07 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| SC 13G | 2025-02-10 | 2025-02-10 | View Filing |
| SC 13G/A | 2025-02-05 | 2025-02-05 | View Filing |
| SC 13G/A | 2025-01-30 | 2025-01-30 | View Filing |
| SC 13G | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 8-K | 2024-12-16 | 2024-12-16 | View Filing |
| 424B5 | 2024-12-13 | 2024-12-13 | View Filing |
| 424B5 | 2024-12-12 | 2024-12-12 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| 424B5 | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 8-K | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-16 | 2024-05-16 | View Filing |
| 4 | 2024-05-13 | 2024-05-13 | View Filing |
| 4 | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| SC 13G | 2024-04-26 | 2024-04-26 | View Filing |
| 8-K | 2024-04-17 | 2024-04-17 | View Filing |
| 424B5 | 2024-04-17 | 2024-04-17 | View Filing |
| ARS | 2024-04-15 | 2024-04-15 | View Filing |
| DEF 14A | 2024-04-11 | 2024-04-11 | View Filing |
| 10-K | 2024-03-06 | 2024-03-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Liquidity Sweep Strategy | 15.03% | 0.99 | 6 | 0.5 | 1.71 | 5.67 |
| Neural Forcast | 12.59% | 1.11 | 20 | 0.66 | 0.58 | 3.23 |
| Donchian Channel Strategy | 10.38% | 1.1 | 19 | 0.24 | 0.21 | 1.02 |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | x |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxx% | xxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |